BRIEF: Mixue posts strong profit, revenue gains in first post-IPO report
Leading bubble tea chain Mixue Group (2097.HK) on Wednesday said its revenue reached 24.83 billion yuan ($3.42 billion) last year, up 22.3% from 2023, according to its first financial report…
BRIEF: Mixue surges on Hong Kong trading debut
Shares of leading bubble tea chain operator Mixue Group (2097.HK) surged in their Monday trading debut in Hong Kong, opening up 29% from their HK$202.50 IPO price after being heavily…
NEWS WRAP: Nayuki COO leaves amid growing challenge from larger peers
The bubble tea chain announced the senior executive departure days after it was ousted from the benchmark Hang Seng Composite Index By Teri Yu Nayuki Holdings Ltd. (2150.HK) on Wednesday…
BRIEF: Mixue serves up $444 million IPO
Leading bubble tea chain operator Mixue Group (2097.HK) launched its Hong Kong IPO share sale on Friday, saying it would sell about 17 million shares for HK$202.50 apiece to raise…
BRIEF: Mixue clears Hong Kong listing hearing, aims for early March debut
Leading Chinese bubble tea seller Mixue Group passed its listing hearing with the Hong Kong Stock Exchange, according to its post-hearing information pack released last Friday. After achieving that key…
Hong Kong brews up bubble tea listings. But which ones are the sweetest?
Bubble tea chains Guming and Auntea Jenny took big steps forward on financial markets last Friday
BRIEF: Guming passes Hong Kong listing hearing in bubble tea race to market
Bubble tea chain operator Guming Holdings Ltd. has passed its Hong Kong listing hearing, clearing the last major regulatory hurdle before its planned IPO, according to information from the Hong…
Recent Articles
RELATED ARTICLES
-
Mixue pours up strong growth in China’s overheated bubble tea market
- IPO tea party set to resume with Guming’s regulatory nod from China?
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- Weak sentiment may leave Auntea Jenny thirsty for better valuation
